Table 3:
Relative SUVmax values for respective clinical contexts and PET-bone scan concordance.
| Timing | N | FDG-Avid Lesion Reported n/N (%) |
Max SUV FDG-PET Values, median [r] | PET-Bone Scan Concordance |
|---|---|---|---|---|
| Primary Site – Pre-Chemotherapy | ||||
| Diagnosis | 11 | 11/11 (100) | 7.4 [2.0–16.2] (n=9)a |
NA |
| Resection with macroscopic residual disease | 4 | 4/4 (100) | 4.6 [3.3–7.0] (n=4) |
NA |
| Resection with no residual disease | 6 | 4/6 (67) | 2.2 [1.5–2.8] (n=2)a |
NA |
| Primary Site – Post-Adjuvant Chemotherapy | ||||
| Chest Recurrence Pre-Treatment | 8 | 8/8 (100) | 6.1 [1.6–12.7] (n=8) |
NA |
| Surveillance | 16 | 5/16 (31) | 3 [1.3–5.3] (n=5) |
NA |
| Metastatic Disease – Pre-Chemotherapy | ||||
| Distant Bone Metastasis at Diagnosis | 3 | 3/3 (100) | 2.5 [2.0–3.8] (n=3) |
100% (3/3) |
| Distant Bone Metastasis at Relapse | 2 | 2/2 (100) | 3.2 [2.9–3.4] (n=2) |
100% (1/1) |
| CNS Metastasis | 3 | 0/3 (0) | NA | NA |
CNS = central nervous system, FDG-PET = fluorodeoxyglucose-positron emission tomography, GTR = gross total resection, n = number, N = number assessed, r = range, SUV = standardized uptake value
a
– Two patients without SUVmax value reported